J&J, Genmab reveal first-line data for Darzalex Faspro, plus new mantle cell lymphoma results for Imbruvica-Venclexta: #ASH23
The late-breaking abstracts for next month’s American Society of Hematology meeting in San Diego were released Tuesday morning. Here are three notable studies from drugmakers testing therapies in different blood cancers and disorders:
J&J, Genmab reveal first-line data for Darzalex Faspro in multiple myeloma: Researchers have been attempting to move Darzalex Faspro, the subcutaneous version of the cancer therapy Darzalex, into earlier lines of treatment. Johnson & Johnson on Tuesday reported data from a Phase III trial dubbed PERSEUS comparing the treatment to the standard of care in the frontline setting. Darzalex Faspro on top of the standard of care significantly improved progression-free survival (PFS) rates in 709 patients after 47.5 months. Median PFS was not reached in either arm, but the therapy recorded a hazard ratio of 0.42 and a p-value of p<0.0001.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.